Biology of Blood and Marrow Transplantation
Volume 15, Issue 6 , Pages 671-678 , June 2009

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD

  • Suzanne van Dorp

      Affiliations

    • Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
    • Department of Immunology, UMC Utrecht , The Netherlands
    • ,
  • Floor Pietersma

      Affiliations

    • Department of Immunology, UMC Utrecht , The Netherlands
    • ,
  • Matthias Wölfl

      Affiliations

    • Children's Hospital, University of Würzburg, Germany
    • ,
  • Leo F. Verdonck

      Affiliations

    • Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
    • ,
  • Eefke J. Petersen

      Affiliations

    • Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
    • ,
  • Henk M. Lokhorst

      Affiliations

    • Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
    • ,
  • Edwin Martens

      Affiliations

    • Julius Center for Health Sciences and Primary Care, UMC Utrecht, The Netherlands
    • ,
  • Matthias Theobald

      Affiliations

    • Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
    • ,
  • Debbie van Baarle

      Affiliations

    • Department of Immunology, UMC Utrecht , The Netherlands
    • ,
  • Ellen Meijer

      Affiliations

    • Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
    • ,
  • Jürgen Kuball

      Affiliations

    • Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
    • Department of Immunology, UMC Utrecht , The Netherlands
    • Corresponding Author InformationCorrespondence and reprint requests: Jürgen Kuball, MD, Department of Hematology, Department of Immunology, University Medical Centre Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands.

Received 16 October 2008 ,Accepted 16 February 2009.

References 

  1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–389
  2. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005;105:4200–4206
  3. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation. 1988;46:238–240
  4. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007;150:197–214
  5. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505–511
  6. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004;104:2603–2606
  7. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756–762
  8. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273–277
  9. Kebriaei P, Saliba RM, Ma C, et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant. 2006;38:203–209
  10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304
  11. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956
  12. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–233
  13. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995–1001
  14. Cartron G, Blasco H, Paintaud G, Watier H, Le GC. Pharmacokinetics of rituximab and its clinical use: thought for the best use?. Crit Rev Oncol Hematol. 2007;62:43–52
  15. Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007;122:139–145
  16. Antin JH. Reduced-intensity stem cell transplantation: “… whereof a little More than a little is by much too much.” King Henry IV, part 1, I, 2. Hematology Am Soc Hematol Educ Program. 2007;2007:47–54
  17. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685–3691
  18. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117:524–529
  19. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant. 1995;16:289–295
  20. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987–992
  21. Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood. 2006;108:2485–2492
  22. Nguyen VH, Shashidhar S, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008;111:945–953
  23. Zhao D, Zhang C, Yi T, et al. In vivo activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic GVHD. Blood. 2008;112:2129–2138
  24. Yi T, Zhao D, Lin CL, et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft versus host disease. Blood. 2008;112:2101–2110

 Financial disclosure: See Acknowledgments on page 677.

PII: S1083-8791(09)00106-2

doi: 10.1016/j.bbmt.2009.02.005

Biology of Blood and Marrow Transplantation
Volume 15, Issue 6 , Pages 671-678 , June 2009

Article Tools

* Image Usage & Resolution